Light Mode
$0.1599 ↑ +0.0049 (+3.16%) Trading Up from the previous close of $0.1550
-0.15 (-49.63%) / 6M
Momentum, market sentiment, and recent alerts
AIM reads not so good: price sits below both the 20- and 200-day averages, short interest is falling month over month, the 12-month move is -90.1%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.